Blood Conservation in Adult Cardiac Surgery, What is the Way Forward in Today's Practice?
NCT ID: NCT02595385
Last Updated: 2015-11-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
240 participants
INTERVENTIONAL
2015-02-28
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery
NCT06230198
Cell Salvage and Retrograde Autologous Priming
NCT04792814
Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers.
NCT02053818
Cell Savers and Blood Quality
NCT02046824
Exploration of Cerebral Pathophysiology During and After CABG Using CPB
NCT02941380
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is a prospective, randomised controlled trial with 240 patients undergoing a single procedure adult cardiac surgery that will be randomised to either full crystalloid prime volume or RAP, with or without cell salvage. There will be four study arms;
1. RAP alone
2. Cell Salvage alone
3. RAP plus cell salvage
4. Control group
Results will follow analyse of the data using a logistic regression using a design matric with blood transfused as a key explanatory variable with scope to add in patient covariables. It is expected that date will be analysed after 100 patients and if significance is achieved then the study can be terminated.
The study will aim to identify those patients that receive a blood transfusion intra or post-operatively. Symptomatology from anaemia is subjective and hard to measure. The studies linking transfusion to cardiac surgery outcomes are retrospective; despite careful risk adjustment, it is possible that these associations reflect a tendency amongst clinicians to transfuse the most critically ill patients or miss another important confounder.
In 2001, Spiess referred to current transfusion practice as a 'silent epidemic'. His description is still accurate. In 2006, almost half of all patients undergoing coronary artery bypass grafting in the united states received blood transfusion and the probability of receiving blood is greater when procedures are more complex. Although the infectious risk of blood transfusion have been successfully minimised the weight of evidence increasingly suggests that transfusing less in stable patients could prevent a significant amount of morbidity and mortality. This study will help guide management in those in whom transfusion is avoidable.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RAP
Retrograde Autologous Prime of the bypass circuit. To remove 500-900ML of fluid.
Retrograde Autologous Prime
Removal of fluid from the bypass circuit
CS
Reinfusion of shed blood during the operation
Cell Salvage
Reinfusion of shed blood during the operation
RAP and CS
RAP and CS used in combination
Cell Salvage
Reinfusion of shed blood during the operation
Retrograde Autologous Prime
Removal of fluid from the bypass circuit
Control
No intervention
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cell Salvage
Reinfusion of shed blood during the operation
Retrograde Autologous Prime
Removal of fluid from the bypass circuit
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing single procedure surgery
* Be on single anti-platelet therapy
* To have stopped warfarin pre-operatively with a INR of \<1.5
* Have stable coronary disease
* Have good Left Ventricular function
Exclusion Criteria
* Emergency Surgery
* Be on dual antiplatelet therapy
* Have pre-operative kidney dysfunction with eGFR \<60ml/min
* Have post-operative drainage \>200ml per hour or require re-exploration for bleeding.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Belfast Health and Social Care Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alison Murphy
Research Administrator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Reuben Jeganathan
Role: PRINCIPAL_INVESTIGATOR
Belfast Health and Social Care Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medicine
Belfast, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
134964
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.